Drug Profile

TO 207

Alternative Names: TO-207

Latest Information Update: 28 Jan 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Torii Pharmaceutical
Class Amino acids; Anti-inflammatories; Benzamides; Essential amino acids; Small molecules
Mechanism of Action Cytokine inhibitors; Inflammation mediator inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Jan 2024 No recent reports of development identified for preclinical development in Immunological-disorders in Japan
07 Dec 2019 Preclinical trials in Immunological disorders in Japan (unspecified route)
07 Dec 2019 Pharmacodynamics data from in vitro studies in Immunological disorders (Cytokine release syndrome) presented at the 61^stAnnual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2019)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com